Table 1.

The KRAS allele in NSCLC in case-control studies

A. Association between KRAS variant allele and NSCLC in the New Mexico case-control study
GroupGenotypeCrude ORPAdjusted OR *P
Overall (218 cases vs 325 controls)
TT1.0
TG+GG1.4 (0.9–2.3)0.131.5 (0.9–2.4)0.15
Pack-years <41 (75 cases vs 195 controls)
TT1.0
TG+GG2.3 (1.1–4.4)0.022.3 (1.1–4.6)0.02
Pack-years ≥41 (143 cases vs 130 controls)
TT1.0
TG+GG1.0 (0.5–1.9)0.990.9 (0.5–1.8)0.86
B. Association between KRAS variant allele and NSCLC in the Boston case-control study
GroupGenotypeCrude ORPAdjusted OR P
Overall (2,205 cases vs 1,497 controls)
TT1.0
TG+GG1.11 (0.93–1.32)0.231.17 (0.97–1.44)0.15
Pack-years § <40 (956 cases vs 1,214 controls)
TT1.0
TG+GG1.28 (1.03–1.60)0.031.36 (1.07–1.73)0.01
Pack-years ≥40 (1,249 cases vs 283 controls)
TT1.0
TG+GG0.85 (0.61–1.29)0.340.89 (0.63–1.25)0.49
  • * Age, race, gender, and smoking status were adjusted in an unconditional logistic regression model.

  • 41 pack-years is the median of 543 smokers.

  • Age, gender, smoking status, pack-years of smoking and years since smoking cessation (if exsmoker) were adjusted in an unconditional logistic regression model.

  • § 40 pack-years is the median of 3702 smokers.